Tenaya Therapeutics, Inc. stock is up 9.83% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 November’s closed higher than October.
Tenaya Therapeutics, Inc. discovers, develops, and delivers therapies for heart disease in the United States. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) and gDCM. It is also developing a small molecule inhibitor of histone deacetylase 6 for use in heart failure with preserved ejection fraction (HFpEF)